Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They fail to mention that they have discovered the only UNIVERSAL cancer marker. That is the key element to catch some eyeballs of new investors. They also don't educate the investors on all the different cancers tested of which there are no present markers until Recaf.
At some point we will dry up all the selling, but that can only take place if we attract many more new investors. If we had a product out on the market I bet we would be approached to be bought. I know that Dr Moro was adamant about not selling the company. He had envisioned 3 seperate companies within 1 company or the possibility of splitting into 3 companies. Diagnostics/Imaging/Therapeutics. All I know is he has something unique and special and IMO you would have to be desperate or not convinced of this. However, I am anxious to see what's next. The doors are finally opening why would you run when no one is screaming "fire."
There are 41 millions shares outstanding. If we were to get bought how would the warrants work? That is why we are selling under 3 or 4 dollars based on projected revenue. People he made deals with to keep the company afloat have an opportunity to buy shares from the company for much less than todays prices.
If the sellers were to ask at the open for 1(+) dollars the bid would have moved up along with it. There is such desperation to follow these ridiculously low bids. Doesn't anyone understand what we have. It can't be copied or made in a generic form. Wake up. You are selling the only sure investment to own in this turbulent market.
They sabotaged the company by handing out warrants attached to all the stock they sold or gave away. This sad. I'm calling Donald Trump. Wittenberg......YOUR FIRED!!!!!!!!!
Dilution has created too much of a headwinds for us to go anywhere.
Why are they saying after 3 years of testing by BioCurex?
"as the press release states that more than three years of testing by BioCurex has confirmed RECAF's high degree of clinical sensitivity and specificity in detecting various types of cancer, even when the disease is at its earliest stage. RECAF (the receptor for alpha-fetoprotein) is a wide-spectrum marker present in malignant cancer cells and absent in most normal cells, allowing it to play a major role in the development of new diagnostic tests for prostate, breast, colorectal, lung and other cancers."
They have been testing and gathering data for Recaf for close to 10 years when the company started in 1997.
They should have also said that we have validated data by independant labs and scientists in and outside of the US where we hold 22 patents.
This is a link to Inverness message board
http://messages.finance.yahoo.com/mb/IMA
This is a pretty good profile of our company.
http://investing.businessweek.com/research/stocks/people/people.asp?symbol=BOCX.OB
I just went to yahoo finance and came from Inverness (IMA) stock message board and the only posts I saw were very positive on BioCurex. They aren't as active as we are, but we can change that. We should have been on the Abbott board as well. If management won't do their job we'll have to show them how to get the attention of their shareholders. Hope to see you guys over at IMA and ABT chatrooms.
We are close to commercialization, but there is strict gag order in the licensing contract with Abbott, so we will not hear anything about their progress. This was absolutely great for us, because now Abbott will be forced to get this to the market in a hurry. The other thing that will help us is that we now will have help with the point of care test. I Googled us and Inverness and see we are in Investors Business Daily online, Yahoo, MSN, Biospace, and Pharmadeals. We need some television coverage. I would suggest they go back to GE and license the imaging, so we can get on CNBC.
The damage is now evident with the dilution. We waited almost 3 years for this since Abbott, and we end up a few pennies. We have to get better management. I'm not afraid to say it, and today represents why. The technology is so extremely unique and truly a Godsend. An experienced leader is warranted at this stage. Inverness did not get to where they are by luck or good fortune, they are agressive and have impressed the investment community. Obviously management has not.
Inverness is a very "hot" stock with huge upward momentum. There are alot of eyeballs watching their every move. I am very excited that we have licensed to them. IMO this will get us some much needed attention. Remember that thru the eyes of Inverness an Abbott they aren't trying to help us, because it would be counter-intuitive in regards to their best interest. It is now up to Terry to get to work using the proper channels to get us exposure. They created some daylight now it's time for BioCurex to turn up the heat.
Inverness was one of the top ten most searched stocks on TheStreet.com. When it hits their website we should quench the selling, but this was the cost we are paying for their dilution of shares. I am going to follow up with another letter to Motley Fool and tell them to take a second look at BioCurex before they are too late to the party.
We are holding 2 Aces. This is a great time to double down.
As soon as we meet the requirements to get listed we have to get on a normal stock exchange and stop listing SEC documents under Whispering Oaks. I wonder if Dr Wittenberg is practicing today?
Think about what happened today. We are again validated after close to 3 years since Abbott. Before this morning I would consider this a very speculative stock. Now I am comfortable and forsee tremendous upside. Thank you to everyone on this board that contributed and continued to give us hope when management failed to communicate. They are probably wondering how to handle the press release with the legal dept at Abbott.
Now let's see how management gets the word out. Please don't punish your loyal shareholders with more dilution. Terry, do your thing. I hope to see some REAL exposure. We are validated once again. This company is still crawling. I can't wait to see what happens when we get our feet stable on the ground. Expect Recaf to be a household name. That is my prediction. How can there be anyone selling. We will see royalties this year. We just got another correct number on our lottery ticket. This has been a good week for me.
It is extremely important for BioCurex to sign another licensee to force Abbott to sprint toward the finish line. I have a feeling that when we see an announcement it will be just before the market opens to catch everyone off guard and give us a much needed shot in the arm. I would be content to know that Dr Moro is presenting at any upcoming diagnostic or oncology meetings in the near future. At least make an effort to convince the medical community that we are about to have Recaf commercialized. The lack of communication is cause for people to have doubts as to our progress. It is natural for any investor to be concerned, especially a biotech company. I call frequently, and I have no reason to doubt their enthusiasm about our future, but a majority of shareholders are really left out in the cold. If this company is to be successful at this stage of the game there should be monthly updates on their website.
That could be a ploy. Why would they show their cards if it would only cause a bidding war. I'm not referring to them buying us, only that it would be extremely foolish.
Isis is not a one drug wonder. They will have a huge pipeline of drugs. They will become a goliath.
Definitely HOLD ISIS. They have unbelievable technology that works on a genetic level unlike any other biotech company. They are working with RNA not DNA. They have air tight patents. Do not sell. This is a longterm play. You can always sell half that way you won't be disappointed either way. Good luck.
I feel the same frustration everyone here does. It just seems illogical that we aren't getting noticed. We can all be an important part of seeing this become a major biotech company. Today I was rewarded for my patience with another investment I saw grow from the ground floor into a company now given almost a billion dollars to corroborate on a cholesterol drug. It was called Isis Pharmaceuticals. I never gave up and bought at around 4 dollars maybe 6 or 7 years ago and today it is over 22 dollars and will now be given its deserved valuation.
I feel even stronger about Biocurex. From all of my own due diligence and waiting over 4 years I see big things on the horizon. We can all do something to help promote BioCurex and we will all benefit.
We just need to get the message out there. It is like politics. Knock on enough doors and someone will eventually answer.
I recently wrote this letter to Motley Fool Investment Advisors:
I feel compelled to tell you about a small biotech company, BioCurex (BOCX), that has worldwide patents on the discovery of the only proven UNIVERSAL cancer biomarker. They can discriminate whether you have ANY form of cancer ANYWHERE in your body from one drop of blood. They have a scientific board unlike any other which includes the discoverers of the prostate and colon cancer markers. They have inked a deal with Abbott and are in the process of many other negotiations to license the technology worldwide. The lead scientist and founder, Dr Ricardo Moro, was the discoverer of the marker called Recaf. He has converted the test most recently from a radioactive assay into a chemoluminescent assay whereby this has been independently tested to work on Abbott's automated analyzers. Not only can you walk into your doctor's office and find out that you may have cancer by just a drop of your blood, they are working on and have successfully prototyped an instant rapid test similar to a pregnancy test. Recaf also has many other uses such as tumor imaging. It "lights up" only the cancer cells because there is an affinity for the receptor on the cancer cells only. The most exciting discovery is in the treatment of cancer. They have found that by having only an affinity for the receptor only on the cancer cells they can effectively irradicate the cancer cells without damaging normal or healthy cells. Just think about how this will change healthcare as we know it worlwide. It will save billions of dollars by early detection, save people from unnecessary surgical biopsies, and save lives. Please do your own due diligence by going to the BioCurex website and just read some of their past press releases. I promise that this isn't theoretical, it is for real. I would appreciate it if you respond back to me after you really had a chance to "take it all in."
Thanks for the opportunity and I hope I have enlightened you. I am a shareholder that wishes to give you and your readers an opportunity to help fight cancer, and profit at the same time. I know BioCurex is onto something truely unimaginable and I only hope that the we will all see this technology come to fruition sometime early this year.
For those of you in doubt about Abbott, I know they are very stealth about Recaf, but we are mentioned when they talk about cancer markers. Here is what I found in one their oncology memos......
Future Tumour Markers
To supplement these established cancer assays,
Abbott researchers are working on developing
immunoassays for a number of additional, cuttingedge
tumour markers.
Table 1
Abbott Tumour Markers.
Another marker under development is receptor for alpha-fetoprotein-fatty
acid complex (RECAF). Existing data from
prototype assays have demonstrated both high
sensitivity and high specificity for the early detection
of several major types of cancer including breast,
colorectal, prostate, ovarian and lung.
............................................................................................................................
Abbott is still on board, things are obviously progressing.
IMO, Whoever is selling now is going to deeply regret it.
There is alot to be optimistic about. This is definitely going to be our year. I expect we will hear something this week or next. Everything I have researched has given me all the faith I need to know we will succeed. The key to our success will be Dr Moro. His years of research and clear understanding of the recognition and mechanism behind the formation of cancer will give us the best chance of finding a cure. I would like to see us collaborate with several other biotech companies with enough experience and monetary backing to take us to the next level. He should not go about this alone. We need an army of workers. Think big and we will be big. That is my mantra. The interview on BusinessTV was encouraging and it appears that everyone is very motivated and truly wants the company to succeed. We will be rewarded soon.
It only further substantiates that the technology is for real and no one knows more about Recaf that Dr Moro. The company WAS Protokinetix.
Terry, I have a question about us licensing and our a patent in regards to Recaf. Read this.................
--------------------------------------------------------------------------------
STOCK ALERT
RJV Networks, Inc. (OTC BB: RJNV)
Press Release----Source: RJV Network, Inc.
http://biz.yahoo.com/n/r/rjvn.ob.html
(OTC BB: RJVN) Announces Cancer Treatment Therapy
Advances Using BioCurex RECAF Technology Through A
Licensing Agreement with its BioKinetix (acquisition
underway).
Thursday December 19, 10:00pm ET
http://finance.yahoo.com/q?s=rjvn.ob&d=t
RJV Network, Inc. (OTC BB:RJVN.OB - News), a Nevada
corporation, is in the process of acquiring BioKinetix
Research Inc. BELLEVUE, Wash., and announces further
developments of the combined Company revolutionary cancer
treatment therapy, now just months away from formal market
testing to begin.
BioCurex Inc. announced on December
16th that it has completed a licensing agreement with
BioKinetix (being acquired by OTC BB: RJVN) to use
BioCurex's RECAF technology. The license will allow
BioKinetix to use its InNexus Super Antibody platform
technology to create therapeutic antibodies; then combining
RECAF antibodies with RJVN Super Antibody technology could
give BioKinetix the potential to create both highly potent
therapeutic antibodies, as well as vaccines to immunize
against the RECAF receptor, creating a highly effective
treatment for most cancers as agreed upon by many world
renowned molecular biologists, including Dr. John Todd
of RJVN BioKinetix.
BioCurex, Inc. is a biotechnology company that is
developing products based on patented / proprietary
technology in the areas of cancer diagnosis, tumor imaging
ad therapeutics. The technology identifies a cancer marker
known as RECAF(tm), which is found on malignant cells from
a variety of cancer types but absent in most normal or
benign cells. Detailed information about BioCurex may be
obtained from their website at biocurex.com .
Created over ten years of expensive research and
development, RECAF technology is able to effectively
locate molecules (markers) that are present on active
cancer cells, but not on healthy cells. The combination
of these two technologies gives BioKinetix the potential
to create a series of therapeutic products that may treat
most cancers. The therapeutics to be developed are
monoclonal antibodies that mark growth factor receptor
on cancer tissue. Combining RECAF antibodies with Super
Antibody technology will give BioKinetix the potential
to create both highly potent therapeutic antibodies, as
well as vaccines to immunize against the RECAF receptor.
On behalf of the Board of Directors,
Mr. Edward Velton, President
Contact: For RJV Network, Inc. Grant Young
Company Name----------------RJV Networks, Inc.
Symbol----------------------RJVN
Current Price---------------$0.10
52 Week High----------------$2.10
52 Week Low-----------------$0.10
Target $4 -to- $6 Q3/2003
Investment Highlights
RJVN projects it will be able to treat most cancers with
its combined targeted therapy treatment which is based
upon an astounding discovery by a molecular biologist
at the Univ. of Michigan - The causal link to breast
and most other malignancies and cancers in the protein
Mammastatin.
RJVN has developed a series of cancer treatment therapies
which utilize pan-cancer market antibodies. Antibody
therapies do not create chemical toxicity and, as such,
are fast tracked through the regulatory approval process.
Using this approach, RJVN is targeted to enter testing
for its products in six months.
RJVN's combination of two leading, well known technologies
previously announced by BioCurex and InNexus Corp along
with RJVN's key MAb protein replicating technology has
allowed the Company to create a series of patented
therapeutic products that many molecular biologists
believe will treat most cancers.
RJVN's R&D and Management are led by Dr. John Todd,
Dr. Charles Morgan (a world renowned molecular biologist
and 5 other industry leading Dr's all with several
years experience in bio-tech development.
................................................................................................................................................................................................
Everyone on this board don't get overly excited. This was dated 2003.
However, I did a quick search on EDGAR under heading Recaf and Dec 27, 2007 Innexus was specific in saying they are using monoclonal antibiotics targeting the receptor for Recaf. What is up with this?
Bottom line is we will all be rewarded. The technology is beyond anything else in biomarker discovery. I sense the next wave of news will reassure everyone that we were all right to hang in there. Everyone knows how I feel about management's previous press releases and I can only hope we don't see more paid dilutive hype and we get the deserved real media attention. The news should be great, but learn from your mistakes and take the high road this time. All you are creating by paying for media coverage is an opportuntity for a quick trade. We need long term investors that share our vision. This has never been a short term trade for me as evidenced by the fact I have been adding to my position over a 4 year period. I am concerned that if Wittenberg continues this route of paying for hype all momentum will be lost to day traders. Let's get the backing of all governments with socialized medicine. We can save lives and it makes economic sense. Many of the Fortune 500 companies are there because of governmental contracts. Think bigtime and we will be bigtime.
ALL assets are collatoral in the 3,000,000 hedgefund placement. Dr Moro would lose everything as well as shareholders to them. I happen to be more optimistic than ever.
Dr Moro is very gifted in his research endeavors and he will soon be recognized worldwide when he gets awarded the Nobel Peace Prize for Recaf.
Anyone selling at this price is definitely desperate or has completely given up. Fortunately, the technology has gotten noticed and it will become a must have to all diagnostic labs and research centers.
I believe we will see Recaf become to Biocurex what Ipod has become to Apple. We will be rewarded, but let's make it a sure fire winner with an experienced CEO immediately following the next infusion of cash.
IMO the next wave of press releases will be big news that will get us firmly grounded and established as a true company once and for all. Once the news is released we HAVE TO get a real CEO....not a friend of Dr Moro. But frst things first let's close the some deals!
We are in a "holding pattern."
I call Terry frequently. I have repeatedly advised everyone to do the same. The hold up on the news is that they refuse to preannounce anything, but I am frequently reassured that my patience will be rewarded. I have to give them the benefit of the doubt at this point. They have delivered great news from the ISOBM, and Dr Moro is being extremely paranoid for good reason. He has Abbott looking over his shoulder from one side with a gag order and strict confidentiality, and the SEC looking over the other to make sure there is no funny business, so he wants to scream loudly to the world what he has. but he is reluctant. I am never given specifics, but word is that there is certainly nothing to worry about, quite the contrary. Every time I mention the share price, I am told that this will soon be rectified when they are free to disclose the upcoming news.
IMO, we are looking at anywhere from tomorrow till the end of January. Let's hope it's sooner rather than later. I am still convinced we will see great things happen for this company, but I will never take back the way I feel about us not having a reputable CEO. That is very high on my list. He has caused me to second guess everything about this company, and I know beyond a shadow of doubt we would be in a much better place right now.
At this point, and after talking to Terry I feel comfortable letting it ride for another couple weeks. There will always be selling for tax purposes at this time, and we always know the volume will likely spike before any big news.
Kag.....where are you? Any regulation on negative posting. The last post is nonconstructive and should be removed, such as exlax's last post.
Another day of just more of the same.....nothing.
My problem is with their inability to close additional licenses. We will pop higher than this stock has ever risen. Anyone would be a fool to sell this stock when the future of this company would look brighter than ever. That is why it is so important to roll up their sleeves, make some concessions and just sign some agreements. The day we get FDA approval I would be at the doorstep of every Health Commissioner of every socialized country in the world.
The requirement is a "clinical" setting. That means no blind samples. The test is complete, we have mentioned that Dr Moro has already commented on this. He clearly has moved on.